A Phase Ⅲ Comparative Study of QL2108 to Dupixent®

NCT06884891 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: QL2108 injection
DRUG: Dupixent®

Sponsor

Qilu Pharmaceutical Co., Ltd.